These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 18181037)

  • 1. Differentiation syndrome in non-M3 acute myeloid leukemia treated with the retinoid X receptor agonist bexarotene.
    DiNardo CD; Ky B; Vogl DT; Forfia P; Loren A; Luger S; Mato A; Tsai DE
    Med Oncol; 2008; 25(3):299-302. PubMed ID: 18181037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence of myeloid differentiation in non-M3 acute myeloid leukemia treated with the retinoid X receptor agonist bexarotene.
    Tsai DE; Luger SM; Kemner A; Swider C; Goradia A; Tomczak E; DiPatri D; Bagg A; Nowell P; Loren AW; Perl A; Schuster S; Thompson JE; Porter D; Andreadis C; Stadtmauer EA; Goldsteini S; Ghalie R; Carroll M
    Cancer Biol Ther; 2007 Jan; 6(1):18-21. PubMed ID: 17204865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemia.
    Tsai DE; Luger SM; Andreadis C; Vogl DT; Kemner A; Potuzak M; Goradia A; Loren AW; Perl AE; Schuster SJ; Porter DL; Stadtmauer EA; Goldstein SC; Thompson JE; Swider C; Bagg A; Mato AR; Carroll M
    Clin Cancer Res; 2008 Sep; 14(17):5619-25. PubMed ID: 18765556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induced differentiation of acute myeloid leukemia cells by activation of retinoid X and liver X receptors.
    Sanchez PV; Glantz ST; Scotland S; Kasner MT; Carroll M
    Leukemia; 2014 Apr; 28(4):749-60. PubMed ID: 23823656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retinoid receptor expression and its correlation to retinoid sensitivity in non-M3 acute myeloid leukemia blast cells.
    Lehmann S; Paul C; Törmä H
    Clin Cancer Res; 2001 Feb; 7(2):367-73. PubMed ID: 11234892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AML.
    Welch JS; Niu H; Uy GL; Westervelt P; Abboud CN; Vij R; Stockerl-Goldstein KE; Jacoby M; Pusic I; Schroeder MA; Dipersio JF; Cashen AF
    Am J Hematol; 2014 Aug; 89(8):E103-8. PubMed ID: 24723466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rexinoid-triggered differentiation and tumor-selective apoptosis of acute myeloid leukemia by protein kinase A-mediated desubordination of retinoid X receptor.
    Altucci L; Rossin A; Hirsch O; Nebbioso A; Vitoux D; Wilhelm E; Guidez F; De Simone M; Schiavone EM; Grimwade D; Zelent A; de Thé H; Gronemeyer H
    Cancer Res; 2005 Oct; 65(19):8754-65. PubMed ID: 16204045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide.
    Sanford D; Lo-Coco F; Sanz MA; Di Bona E; Coutre S; Altman JK; Wetzler M; Allen SL; Ravandi F; Kantarjian H; Cortes JE
    Br J Haematol; 2015 Nov; 171(4):471-7. PubMed ID: 26205361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tamibarotene.
    Miwako I; Kagechika H
    Drugs Today (Barc); 2007 Aug; 43(8):563-8. PubMed ID: 17925887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preventive and Therapeutic Effects of the Retinoid X Receptor Agonist Bexarotene on Tumors.
    Qi L; Guo Y; Zhang P; Cao X; Luan Y
    Curr Drug Metab; 2016; 17(2):118-28. PubMed ID: 26806040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical experience with a new synthetic retinoid, tamibarotene (Am-80) for relapsed or refractory acute promyelocytic leukemia].
    Takeuchi M
    Gan To Kagaku Ryoho; 2006 Mar; 33(3):397-401. PubMed ID: 16531727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful treatment of angioimmunoblastic T-cell lymphoma with the retinoid X receptor agonist, bexarotene.
    Tsai DE; Chong E; Bagg A; Arnoldi S; Svoboda J; Nasta S; Schuster SJ
    Leuk Lymphoma; 2011 Sep; 52(9):1815-7. PubMed ID: 21585279
    [No Abstract]   [Full Text] [Related]  

  • 13. Arsenic-induced pericardial and pleural effusion without acute promyelocytic leukemia differentiation syndrome.
    Ueda K; Nagai S; Miyashita SI; Kaise T; Ichikawa M; Kumano K; Hangaishi A; Nannya Y; Kurokawa M
    Leuk Res; 2010 Jan; 34(1):e25-6. PubMed ID: 19747729
    [No Abstract]   [Full Text] [Related]  

  • 14. Acute promyelocytic leukemia (AML-M3)--Part 1: Pathophysiology, clinical diagnosis, and differentiation therapy.
    Randolph TR
    Clin Lab Sci; 2000; 13(2):98-105. PubMed ID: 11066455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute promyelocytic leukemia (AML-M3)--Part 2: Molecular defect, DNA diagnosis, and proposed models of leukemogenesis and differentiation therapy.
    Randolph TR
    Clin Lab Sci; 2000; 13(2):106-16. PubMed ID: 11066449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. beta2 Integrins are characteristically absent in acute promyelocytic leukemia and rapidly upregulated in vivo upon differentiation with all-trans retinoic acid.
    Wu JJ; Cantor A; Moscinski LC
    Leuk Res; 2007 Jan; 31(1):49-57. PubMed ID: 16764927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retinoic acid syndrome--cardiac complication.
    Dhar AK; Barman PK
    J Assoc Physicians India; 2012 Nov; 60():63-5. PubMed ID: 23767209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of bexarotene on differentiation of glioblastoma multiforme compared with ATRA.
    Heo JC; Jung TH; Lee S; Kim HY; Choi G; Jung M; Jung D; Lee HK; Lee JO; Park JH; Hwang D; Seol HJ; Cho H
    Clin Exp Metastasis; 2016 Jun; 33(5):417-29. PubMed ID: 26957434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differentiating therapy with all-trans retinoic acid in acute myeloid leukemia.
    Tallman MS
    Leukemia; 1996 Apr; 10 Suppl 1():S12-5. PubMed ID: 8618462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retinoid-dependent growth inhibition, differentiation and apoptosis in acute promyelocytic leukemia cells. Expression and activation of caspases.
    Gianni M; Ponzanelli I; Mologni L; Reichert U; Rambaldi A; Terao M; Garattini E
    Cell Death Differ; 2000 May; 7(5):447-60. PubMed ID: 10800078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.